Immunosuppressant therapy.

P. Katz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this chapter, an attempt has been made to discuss the major immunosuppressant agents in use today as well as some of those whose future is as yet undecided. Obviously, not every immunosuppressive modality could be included in this limited space. However, we have endeavored to include agents of practical and theoretical importance to the practicing physician. The therapies discussed here are all hampered by significant degrees of toxicity, which compromises their usefulness and limits their potential. The decision to begin therapy with these agents must be made carefully, and it is incumbent upon the physician to include the patient and patient's family in this process. In many cases, these choices can be based on well-controlled trials in which efficacy has been established. Unfortunately, for many immunologically mediated processes no such studies are available, or those that have been reported are flawed. In such cases, decisions become increasingly difficult. One must then weigh the potential adverse effects of the agent against the possible long-term consequences of witholding such treatment. We can only hope that the continued study of these diseases and the immunosuppressant agents in concert with the development of new, less toxic therapies will make these choices less difficult in the future.

Original languageEnglish
Pages (from-to)167-192
Number of pages26
JournalAdvances in Internal Medicine
Volume29
StatePublished - Jan 1 1984

Fingerprint

Immunosuppressive Agents
Hope
Physicians
Poisons
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunosuppressant therapy. / Katz, P.

In: Advances in Internal Medicine, Vol. 29, 01.01.1984, p. 167-192.

Research output: Contribution to journalArticle

Katz, P 1984, 'Immunosuppressant therapy.', Advances in Internal Medicine, vol. 29, pp. 167-192.
Katz, P. / Immunosuppressant therapy. In: Advances in Internal Medicine. 1984 ; Vol. 29. pp. 167-192.
@article{ca6866e4ff2f4cc094842556abc07806,
title = "Immunosuppressant therapy.",
abstract = "In this chapter, an attempt has been made to discuss the major immunosuppressant agents in use today as well as some of those whose future is as yet undecided. Obviously, not every immunosuppressive modality could be included in this limited space. However, we have endeavored to include agents of practical and theoretical importance to the practicing physician. The therapies discussed here are all hampered by significant degrees of toxicity, which compromises their usefulness and limits their potential. The decision to begin therapy with these agents must be made carefully, and it is incumbent upon the physician to include the patient and patient's family in this process. In many cases, these choices can be based on well-controlled trials in which efficacy has been established. Unfortunately, for many immunologically mediated processes no such studies are available, or those that have been reported are flawed. In such cases, decisions become increasingly difficult. One must then weigh the potential adverse effects of the agent against the possible long-term consequences of witholding such treatment. We can only hope that the continued study of these diseases and the immunosuppressant agents in concert with the development of new, less toxic therapies will make these choices less difficult in the future.",
author = "P. Katz",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "167--192",
journal = "Advances in Internal Medicine",
issn = "0065-2822",
publisher = "Year Book Medical Publishers",

}

TY - JOUR

T1 - Immunosuppressant therapy.

AU - Katz, P.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - In this chapter, an attempt has been made to discuss the major immunosuppressant agents in use today as well as some of those whose future is as yet undecided. Obviously, not every immunosuppressive modality could be included in this limited space. However, we have endeavored to include agents of practical and theoretical importance to the practicing physician. The therapies discussed here are all hampered by significant degrees of toxicity, which compromises their usefulness and limits their potential. The decision to begin therapy with these agents must be made carefully, and it is incumbent upon the physician to include the patient and patient's family in this process. In many cases, these choices can be based on well-controlled trials in which efficacy has been established. Unfortunately, for many immunologically mediated processes no such studies are available, or those that have been reported are flawed. In such cases, decisions become increasingly difficult. One must then weigh the potential adverse effects of the agent against the possible long-term consequences of witholding such treatment. We can only hope that the continued study of these diseases and the immunosuppressant agents in concert with the development of new, less toxic therapies will make these choices less difficult in the future.

AB - In this chapter, an attempt has been made to discuss the major immunosuppressant agents in use today as well as some of those whose future is as yet undecided. Obviously, not every immunosuppressive modality could be included in this limited space. However, we have endeavored to include agents of practical and theoretical importance to the practicing physician. The therapies discussed here are all hampered by significant degrees of toxicity, which compromises their usefulness and limits their potential. The decision to begin therapy with these agents must be made carefully, and it is incumbent upon the physician to include the patient and patient's family in this process. In many cases, these choices can be based on well-controlled trials in which efficacy has been established. Unfortunately, for many immunologically mediated processes no such studies are available, or those that have been reported are flawed. In such cases, decisions become increasingly difficult. One must then weigh the potential adverse effects of the agent against the possible long-term consequences of witholding such treatment. We can only hope that the continued study of these diseases and the immunosuppressant agents in concert with the development of new, less toxic therapies will make these choices less difficult in the future.

UR - http://www.scopus.com/inward/record.url?scp=0021297832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021297832&partnerID=8YFLogxK

M3 - Article

C2 - 6369924

AN - SCOPUS:0021297832

VL - 29

SP - 167

EP - 192

JO - Advances in Internal Medicine

JF - Advances in Internal Medicine

SN - 0065-2822

ER -